Want to create an interactive transcript for this episode?
Podcast: Brain Wellness - the Podcast
Episode: 154. Development of a concussion drug with Michael Wyand
Description: Michael Wyand is CEO of Oxeia Biopharmaceuticals, a clinical-stage biotech company developing new, innovative therapeutics for mild traumatic brain injury (mTBI), known as concussion, and related neuro-metabolic dysfunction. The company has a drug, OXE103, that successfully completed a pilot Phase 2a clinical trial in the fall of 2022. The study showed robust treatment effect across study endpoints. The endpoints were a reduction in symptom burden and improvement in quality of life. The OXE103 responder rate was 85% vs. a baseline of 33%. Michael earned his post-Doc in Comparative Pathology at Harvard Medical School and a PhD in Comparative Pathology at the University...